Ikarian Capital, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Ikarian Capital, LLC
- $573 Million
- Q3 2024
A detailed history of Ikarian Capital, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 426,913 shares of CRNX stock, worth $23.6 Million. This represents 3.81% of its overall portfolio holdings.
Number of Shares
426,913
Previous 588,818
27.5%
Holding current value
$23.6 Million
Previous $26.4 Million
17.32%
% of portfolio
3.81%
Previous 10.67%
Shares
8 transactions
Others Institutions Holding CRNX
# of Institutions
242Shares Held
79.6MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$348 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$345 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$326 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$274 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$247 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.98B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...